Skip to main content
Advertisement
Advertisement

ANVS

ANVS logo

Annovis Bio, Inc.

1.14
USD
Sponsored
+0.02
+1.79%
Sep 14, 15:59 UTC -4
Closed
exchange

After-Market

1.15

+0.01
+0.79%

ANVS Earnings Reports

Positive Surprise Ratio

ANVS beat 11 of 23 last estimates.

48%

Next Report

Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
-$0.40
Implied change from Q2 26 (Revenue/ EPS)
--
/
--
Implied change from Q3 25 (Revenue/ EPS)
--
/
+8.11%

Annovis Bio, Inc. earnings per share and revenue

On Aug 14, 2026, ANVS reported earnings of -0.40 USD per share (EPS) for Q2 26, beating the estimate of -0.46 USD, resulting in a 13.49% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +3.35% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of -0.40 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
logo
Attovia Therapeutics, Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$2.78
Actual
-$4.88
Surprise
-75.25%
logo
Scribe Therapeutics Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$3.03
Actual
-$2.62
Surprise
+13.59%
logo
enGene Therapeutics Inc. Common Stock
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.43
Actual
-$0.47
Surprise
-7.16%
logo
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
logo
Immutep Limited - ADR
Report Date
Sep 01, 2026 For Q4 26
Estimate
$0.00
Actual
-$0.02
Surprise
-2,500.00%
FAQ
For Q2 2026, Annovis Bio, Inc. reported EPS of -$0.40, beating estimates by 13.49%, and revenue of $0.00, 0% as expectations.
The stock price moved up 3.35%, changed from $1.79 before the earnings release to $1.85 the day after.
The next earning report is scheduled for Nov 10, 2026.
Based on 5 analysts, Annovis Bio, Inc. is expected to report EPS of -$0.40 and revenue of -- for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement